RE:RVX NEW POST BLOGThanks Jkj.
I read the article and was wondering "where is the rest of it?". However, I had better not complain because at least they are getting something out their to the BioSpace followers.
This is a step forward. I really like the fact that Don spoke to the
epigenetic aspects of rvx-208 but he needs to have someone (a writer) explain how significant, profound and advanced this is). There is a huge message here and Don gave it at least a bit of a try.
We also had the analyst report this week.
X Analyst Report, CDN$5.85 target https://www.resverlo
RVX Analyst Report, CDN$5.85 target
https://www.resverlogix.com/upload/media_element/208/01/leeuwenhoeck-research-initiation-report-rvx-march-16-2015.pdf
Read more at https://www.stockhouse.com/companies/bullboard/t.rvx/resverlogix-corp#Jjh1xVvmPgv5lyDs.99
So it's moving ahead.
I also have the same concern that everyone has expressed.
I find the following fascinating (and extremely frustrating).
ACC: PCSK9 Inhinitors May Halve Heart Event Risk.
- Novel lipid-lowering drugs suggests big benefit in exploratory trial analysis.
"SAN DIEGO -- The
dramatic LDL cholesterol-lowing impact of the novel PCSK9 inhibitors appear to pay out in a big cardiovascular risk reduction, according to post hoc analysis, which offered an early look at what the big outcomes trials will show."
So what did they achieve.
- In the evolocumab combined post hoc analysis the group on the standard therapy had a MACE (they use adjudicated cardiovascular event) level of 2.18% after a year.
- The test group had a MACE of .95% after a year. So the ABSOLUTE risk reduction was 1.23%points and the RRR was 47% (I calculated 56%) with 95% a confidence interval of 28% to 78%.
- What this means is that if they repeat the experiment there is a 95% chance that the RRR they get will be between 28% and 78%.
So here is a company that can take a nothing event and make it a huge
"finding" and also get all of the support of Nissan and other scientists and fast track phase 3 trial!!! Amazing!
So what did rvx-208 achieve in the combined ASSURE/SUSTAIN trials?
We know the patient populations are different.
Patient population - patients with diabetes mellitus and CVD
- Absolute MACE at day 210 (just half a year) - control group (Crestor only) = 20.8%
- Absolute MACE at day 210 (just half a year) - test group (Crestor + rvx-208) = 5.1%
- Absolute risk reduction = 15.7% points (a huge number of patients protected at leas until day 210.
- Relative Risk Reduction = 77% and the difference between the test and control is significant at the 99% confidence level (p=.01).
- Also the RRR in the full sample was 55% with p=.02 (98% confidence).
So compare the 2 studies.
- rvx-208 achieved and absolute risk reduction of 15.7% points.
- PCSK9 achieved and absolute risk reduction of 1.23% points.
I recognize that the patient populations are different and not directly comparable but at the most crude comparison level
rvx-208 is 12.8 times more powerful than PCSK9 in MACE reduction and yet PCSK9 gets huge investor, scientific and public profile!
When I look at these numbers I think that I must be completely mis-interpreting the information and if so I would love to have the science posters straighten me out in no uncertain terms. I do know that the patient populations are different, that PCSK9 is an LDL strategy and rvx-208 is an epigenetic BET inhibitor with multiple modes of action including increasing ApoA-l, but still if PCSK9 gets the profile it gets then
why can't RVX get the message out.
Don's comments re trial start concern me but you posters have cleared that up. But even so, with the Emerald Logic FACET predictive modelling and getting ever closer to the FDA approval there will be lot's of important things happening.
I'm so frustrated by their inability to "tell the incredible stories of their achievements" that I could pull my hair out (and I still have some.....hahaha).
The problem is that their culture is at a stage where they do not have a clue about how to get their message out.
Anyway, there are many very positive things happening and my rose coloured glasses tell me rvx-208 is a block buster drug..... oral, relatively low cost and huge patient populations in the USA alone none the less globaly.
Happy spring equinox to all!
Cheers
Toinv :)